Cardiothoracic & vascular anaesthesia
Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial
Authors' conclusion
In this randomized clinical trial, cipepofol provided superior hemodynamic stability as an induction agent compared to propofol at equipotent doses and similar anesthesia depths for patients with AS.
Study context
- Population
- Patients with severe aortic stenosis scheduled for transcatheter aortic valve replacement (TAVR), single centre in China122 analysed
- Participants
- 124 patients
- Comparison
- Cipepofol vs propofol for anesthesia induction
- Cipepofoln = 62
- Propofoln = 62reference
- Primary endpoint
- AUC of the mean arterial pressure (MAP) difference from baseline
- Follow-up
- Initial 15 minutes postinduction
Methodological detailssingle-center, 1:1 randomization, equipotent doses, Randomised June 29, 2023, to July 8, 2024, 1 patient per group excluded (ineligible for TAVR)
- Single-center
- 1:1 randomization
- Equipotent doses
- Randomised June 29, 2023, to July 8, 2024
- 1 patient per group excluded (ineligible for TAVR)
Primary result
As reported in the abstract
AUC of MAP difference from baseline
Cipepofol
−8505.0
median · IQR −12 402.8 to −5130.0 · mm Hg · s
Propofol
−13 189.0
median · IQR −17 006.7 to −7593.3 · mm Hg · s
P < 0.001
Further findings
Postinduction hypotension
P = 0.01
Norepinephrine dose · first 15 minutes postinduction
P = 0.006
Bispectral index
- Comparable in the 2 groups
Original publication
Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial. JAMA Surg. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →